Cluster-randomized trial follow-up reports comparative efficacy of bivalent versus quadrivalent HPV vaccines against cervical precancer, highlighting long-term protection over 15 years.
We report head-to-head comparison of the bivalent and quadrivalent HPV vaccine efficacies against immediate precursors of cervical cancer from 15 years' country-wide cancer registry follow-up of phase III trial cohorts and an age-aligned cohort of unvaccinated women.
No takes yet. Share an insight, caveat, or question.
Lehtinen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: